New Delhi: The Technology Development Board (TDB), under the Department of Science & Technology (DST), Government of India, has extended financial assistance to Acrannolife Genomics Private Limited, Chennai, to support a project focused on indigenous manufacturing of advanced in-vitro diagnostic (IVD) kits.
The initiative aims to strengthen India’s diagnostic capabilities through scalable production, positioning Acrannolife Genomics at the forefront of domestic molecular diagnostics innovation.
The project, titled “Indigenizing IVD Innovation: Establishing a State-of-the-Art Manufacturing Facility to Drive Scalable and Sustainable Growth of Trunome GrafAssure IVD Kits and TBFYND IVD Kits,” will enable Acrannolife Genomics to set up a cutting-edge manufacturing facility.
This facility will focus on large-scale production and deployment of indigenous IVD solutions developed by the company, reinforcing the government’s push towards self-reliance in healthcare technologies.
Also Read: Hyderabad: Advanced Genomics Laboratory Launched by Gene Solutions and AMPATH
Acrannolife Genomics is engaged in developing innovative non-invasive diagnostic technologies based on cell-free DNA and LAMP technology platforms.
These technologies address critical healthcare challenges, including infectious diseases and transplant diagnostics. Through this initiative, Acrannolife Genomics will establish its manufacturing unit at the TANSIDCO Industrial Estate to scale up production of its two key diagnostic products – Trunome GrafAssure and TBFYND.
The company’s flagship product, Trunome GrafAssure, is a laboratory-developed blood test designed for early detection of post-transplant organ rejection and infection in patients undergoing solid-organ transplants.
Leveraging advanced cell-free DNA analysis, Acrannolife Genomics has developed this test to deliver high diagnostic sensitivity and specificity.
It enables clinicians to detect early signs of rejection or infection weeks before the onset of clinical symptoms, supporting timely intervention and improved patient outcomes.
The second product, TBFYND, addresses the urgent need for rapid and accurate detection of tuberculosis, a major public health challenge in India.
Also Read: Recombinant Cells and Sensors Facility Launched at BRIC-RGCB with INR 60 Cr DBT Investment
Acrannolife Genomics: To Establish Platform Facility to Manufacture IVD Kits at Scale
Developed entirely in-house by Acrannolife Genomics, both diagnostic kits are backed by secured intellectual property and integrated with the company’s proprietary software platform, ensuring reliable, scalable, and efficient diagnostic workflows.
With financial support from TDB, Acrannolife Genomics will establish a dedicated platform facility to manufacture these IVD kits at scale.
This move is expected to significantly enhance India’s domestic capabilities in molecular diagnostics while reducing dependence on imported diagnostic technologies.
Speaking on the occasion, Rajesh Kumar Pathak, Secretary, TDB, stated that the Board remains committed to supporting indigenous biotechnological innovations that translate cutting-edge research into affordable and accessible healthcare solutions.
He noted that building advanced manufacturing capabilities in diagnostics will play a crucial role in strengthening India’s healthcare ecosystem and advancing self-reliance in critical medical technologies.
Promoters of Acrannolife Genomics expressed their appreciation for the support extended by TDB.
They highlighted that the assistance will enable the company to scale up production, accelerate the deployment of its diagnostic kits, and expand access to innovative genomic diagnostics for patients and healthcare providers across the country.
